Oncology Expert Insights

Dr. Hochster provides insight into the current gastric/GEJ landscape, spotlighting molecular testing approaches, the roles of chemoimmunotherapy combinations, ongoing research with biomarkers of response, and optimal treatment sequencing for patients with HER2-positive disease.

Dr. Shah and Dr. Wang discuss the management of cytokine release syndrome and neurotoxicity, the referral process, and the need for academic and community collaboration for CAR T-cell therapy in hematologic malignancies.

Bryson Katona, MD, discusses the hallmarks of hereditary diffuse gastric cancer.

Dr. Kalyan and Dr. Mouli discuss the importance of multidisciplinary care in hepatocellular carcinoma, data regarding real-world personalization treatment recommendations, and the benefits of decision-making analysis tools in the space.

Dr. Gradishar discusses the evolution of SERDs in breast cancer, novel SERDs that could shift the paradigm of breast cancer treatment, and ongoing research that could solidify the role of these agents in the field.

Dr. Tagawa discusses the incidence and identification of FGFR alterations in bladder cancer, the approval and use of erdafitinib in the second-line setting for patients with advanced bladder cancer, and research directions with the FGFR inhibitor in the field.

Dr. Yarchoan underscores the unique characteristics of fibrolamellar carcinoma, treatment options for these patients, and ongoing research efforts to expand the limited paradigm in this disease.

Dr. Jain and Dr. Spaggiari highlight key advancements in the treatment of patients with colorectal cancer liver metastases, patient and disease factors to consider during surgical and systemic treatment decisions, and the importance of multidisciplinary care in this patient population.

Dr. Johnson discusses the mechanism of action of VS-6766 alone and in combination with defactinib, expectations for the ongoing phase 2 RAMP 202 trial in KRAS-mutant non–small cell lung cancer, and where the combination could be used in practice pending further positive study results.

Dr. Ilson discusses treatment sequencing for patients with gastric and gastroesophageal junction cancer, the integration of immunotherapy into the frontline setting, and key ongoing studies in the field.

Dr. Gordan discusses the advantages of in-house genomic testing, the transition from external to internal sequencing, and the anticipated effects of the move.

Dr. DeNunzio discusses how proton beam therapy is being used throughout oncology, the advantages of the modality and how it complements other treatment interventions, and where research with the therapy is headed.

Dr. Moore discusses the basis for studying the combination of VS-6766 and defactinib in recurrent low-grade serous ovarian cancer, data that has been generated with the combination from the phase 1/2 FRAME trial, and the potential role for the combination in clinical practice.

Dr. Scott and Dr. Torres-Roca discuss their research of a pooled retrospective analysis exploring genomic-adjusted radiation dose–based radiation therapy in solid tumors and what using genomics to guide radiation dosing decisions could mean for oncology practices.

Dr. Aggarwal and Dr. Girard discuss the significance of the 5-year survival data from the pivotal PACIFIC trial and the real-world benefit of the study regimen in patients with unresectable stage III non–small cell lung cancer.

Dr. Dietrich discusses the latest developments with immunotherapy and targeted therapy in stage III non–small cell lung cancer.

Dr. Neel discusses the momentum of molecularly-driven research and treatment strategies in oncology, the continuation of current research trends, and potential future directions throughout the field.

Dr Pegram and colleagues focus on key clinical trials such as DESTINY-Breast01, HER2CLIMB, NALA, and SOPHIA in the setting of advanced HER2-positive breast cancer and discuss the practical considerations of these data.

In the second segment, Dr Pegram and colleagues discuss the clinical implications of the data from select trials in the neoadjuvant and adjuvant settings for patients with HER2-positive breast cancer.

In the first segment, Dr Pegram and colleagues highlight some of the challenges and remaining unmet needs in the management of patients with HER2-positive breast cancer.

Dr. Loaiza-Bonilla discusses approaches to frontline treatment selection in metastatic pancreatic cancer, the effects of adverse effects and toxicities in treatment planning, and treatment options available to patients post gemcitabine-based regimens.

Lisberg discusses the excitement with datopotamab deruxtecan in non–small cell lung cancer and previews anticipated data from the NSCLC cohort of the TROPION-PanTumor01 trial at the International Association for the Study of Lung Cancer 2021 World Conference on Lung Cancer.

Dr. McKay discusses the importance of patient selection in advanced renal cell carcinoma, selecting between available combination regimens, and nuances regarding the timing of treatment in this disease.

Dr. Sosa discusses the rise in thyroid cancer cases, patient risk factors, the financial challenges associated with long-term treatment and testing, and future research directions in the field.

Dr. Sekeres discusses the current unmet needs of patients with higher-risk myelodysplastic syndromes receiving hypomethylating agents, the potential utility of novel combinations in development, and the incorporation of other end points beyond overall survival in clinical trials.

Dr. Krie and Dr. Yuan discussed treatment-related adverse effects one should be aware of and prepared to manage, recommended management strategies for these TRAEs, and important points to emphasize to patients before they begin treatment.

Dr. Chachoua discusses key guidelines for lung cancer screening, the psychological and financial implications of screening, and the opportunities of a screening initiative instated by NYU Langone Health.

Drs. Brown and Kurzrock discuss the current and future applications of next-generation sequencing in breast cancer, the role of tissue-based testing in light of the growing role for liquid-based testing, and some of the emerging technologies that could overcome current barriers to biomarker testing.